(Q35184335)

7 August 2017

1 reference

title

Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders (English)

1 reference

7 August 2017

Anas Younes

1

1 reference

7 August 2017

Bharat B Aggarwall

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

98

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

458-467

1 reference

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The TNF and TNF receptor superfamilies: integrating mammalian biology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

T cell life and death signalling via TNF-receptor family members

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

A matter of life and death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

CD30 in normal and neoplastic cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Serum levels of soluble CD30 in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

CD30 ligand in lymphoma patients with CD30+ tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

CD30 ligand is expressed on resting normal and malignant human B lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Anti-CD30 antibody-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.11524

1 reference

7 January 2021

CD40 and epithelial cells: across the great divide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Diagnostic significance of CD40, CD40L, and CD26 expression in Hodgkin's disease and other lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The soluble CD40 ligand sCD154 in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Regulation of CD40 and CD40 ligand by the AT-hook transcription factor AKNA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The dynamics of life and death of malignant lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

TRANCE is a TNF family member that regulates dendritic cell and osteoclast function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

RANK is essential for osteoclast and lymph node development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Human bone marrow myeloma cells express RANKL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Functional expression of TRAIL by lymphoid and myeloid tumour cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The receptor for the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

TRAIL receptor-2 signals apoptosis through FADD and caspase-8

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

A novel receptor for Apo2L/TRAIL contains a truncated death domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Inhibition of fas death signals by FLIPs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Apoptotic pathways: paper wraps stone blunts scissors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Activation of protein kinase C inhibits TRAIL-induced caspases activation, mitochondrial events and apoptosis in a human leukemic T cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

APO2L/TRAIL expression in human brain tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11524

7 January 2021

Identifiers

DOI

10.1002/CNCR.11524

1 reference

7 August 2017

1 reference